Cardiomyopathy Management and In-Hospital Outcomes in a Tertiary Care Center: Clinical Components and Venues of Advanced Care

Review began 09/24/2021

Review ended 10/25/2021

Published 10/26/2021

© Copyright 2021

Khaled et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Sheeren Khaled ^{1,2}, Emad M. Babateen ³, Faisal Y. Alhodian ⁴, Renad W. AlQashqari ⁵, Reema S. AlZaidi ⁶, Hala Almainani ⁷, Nadin A. Alharbi ⁸, Kawlah E. Samarin ⁷, Amani A. Fallatah ⁵, Ghada Shalaby ^{1,9}

1. Cardiology, Cardiac Center, King Abdullah Medical City, Makkah, SAU 2. Cardiology, Faculty of Medicine, Benha University, Benha, EGY 3. Cardiology, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Centre, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, SAU 4. Surgery and Medicine, King Abdulaziz University, Jeddah, SAU 5. Cardiology, Ibn Sina National College for Medical Studies, Jeddah, SAU 6. Cardiology, Medicine and Surgery, Taif University, Taif, SAU 7. Cardiology, College of Medicine, Umm Alqura University, Makkah, SAU 8. Cardiology, King Abdulaziz University, Jeddah, SAU 9. Cardiology, Faculty of Medicine, Zagazig University, Zagazig, EGY

Corresponding author: Sheeren Khaled, sheeren.khaled@gmail.com

Abstract

Background

There are few reports on the prevalence of different types of cardiomyopathy, clinical presentation, severity, short-term outcomes, and implementation of advanced heart failure treatment. This study aimed to assess the prevalence, clinical background of different types of cardiomyopathy and to identify the candidate for advanced treatment in a tertiary care cardiac center with many advantages

Method

A single-center retrospective cohort study included 1069 patients admitted to our center and diagnosed with cardiomyopathy during 2019 and 2020

Results

Out of 1069 cardiomyopathy patients admitted and diagnosed at our center between 2019 and 2020, 62% had ischemic cardiomyopathy (ICM), 36% had dilated cardiomyopathy (DCM), and 2% had hypertrophic cardiomyopathy (HOCM). ICM patients were older, showed a higher prevalence of both male gender and pilgrims, and they had more frequent cardiovascular risk factors compared to dilated cardiomyopathy group of patients. However, DCM patients with more severe heart failure symptoms (NYHA class III/IV), much worse LVEF, were subsequently considered deemed for aggressive diuretic therapy, and further advanced therapy (Sacubitril-Valsartan and device therapy) compared to ICM patients. ICM patients showed poor in-hospital outcomes compared to DCM group of patients (0.05 and <0.001) for an indication for mechanical ventilation and in-hospital mortality, respectively). Increased age, presence of renal dysfunction and lower LVEF were found the independent predictors of in-hospital mortality among our studied patients

Conclusion

There are discrepancies between DCM and ICM patients. Although DCM patients were younger at age and had fewer cardiovascular risk factors, they presented with severe symptoms and dysfunction, hence more eligible candidates for advanced heart failure treatment, and finally showed a lower mortality rate. Increased age, presence of renal dysfunction and lower LVEF were found the independent predictors of in-hospital mortality.

Categories: Cardiology, Internal Medicine, Therapeutics

Keywords: in-hospital outcomes, advanced care, management, clinical features, cardiomyopathy

Introduction

Cardiomyopathies are a group of disorders affecting the heart muscle leading to problems in the function and structure of the myocardium [1]. It is defined as a heterogeneous group of diseases of the myocardium associated with mechanical and/or electrical dysfunction, which usually (but not invariably) exhibit inappropriate ventricular hypertrophy or dilatation, due to a variety of etiologies that are frequently genetic [2]. Dilated cardiomyopathy is characterized by left ventricular (LV) dilatation and dysfunctional contractility [3], while ischemic cardiomyopathy is caused by a defect in the myocardial perfusion leading to ischemic manifestations [4]. Hypertrophic cardiomyopathy is an autosomal dominant disorder caused by a missense genetic mutation and results from asymmetric septal hypertrophy causing outflow obstruction of the left ventricle [2,3].

How to cite this article

Khaled S, Babateen E M, Alhodian F Y, et al. (October 26, 2021) Cardiomyopathy Management and In-Hospital Outcomes in a Tertiary Care Center: Clinical Components and Venues of Advanced Care . Cureus 13(10): e19054. DOI 10.7759/cureus.19054

With the continuing advancement of cardiomyopathy management; Sacubitril/Valsartan (Entresto), which is a combination of Sacubitril (a neprilysin inhibitor) and Valsartan (an angiotensin receptor blocker) has been recently introduced as a medical therapy [5]. Another strategy is device therapy, which includes cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs) [6].

Little is known about the clinical presentation, severity, short-term outcomes, and implementation of advanced heart failure treatment among cardiomyopathy patients in the Middle Eastern region. King Abdullah Medical City (KAMC) is the only center in the Mecca region providing tertiary care facilities such as revascularization and advanced heart failure treatment. Because of this, it receives most of the cardiomyopathy patients deemed suitable for further workup, including invasive assessment and advanced management. This made us a unique institution to conduct such a study.

This study aimed to review the prevalence and clinical background of different types of cardiomyopathies with the identification of the candidates for advanced treatment in a tertiary care cardiac center and assessing the effect of this treatment on short-term outcomes.

The abstract of this study was presented orally in Cardio Alex 1-4 June 21. Also, it was submitted to ESC congress 2021.

Materials And Methods

Study population

This was a single-center retrospective cohort study in which the data was retrospectively collected from hospital records in KAMC, a tertiary care hospital in Mecca, Saudi Arabia. The study included 1069 patients who were admitted to our cardiac center (either directly from the emergency department or referral cases from other hospitals) and diagnosed with cardiomyopathy during 2019 and 2020.

Ethical approval

This study was approved by the hospital's institutional review board (IRB number 20-660).

Inclusion criteria

Patients were diagnosed based on symptoms of clinical presentation (chest pain and/or heart failure symptoms) and imaging (echocardiographic and coronary angiography) data.

Echocardiography and diagnostic standard criteria

All standard echocardiography parameters were collected: LVEF, LV size, left atrium (LA) size, right ventricle (RV) size and function, assessments of valves including mitral regurgitation (MR), and left ventricular apex for left ventricular thrombus.

- For LVEF, Biplane Method of Disks (modified Simpson's rule; $LVEF = LVEDV - LVESV / LVEDV$) was used for calculation [7].

- For LV size, Biplane Method of Disks (modified Simpson's rule) is used for chamber quantification (Severe LV dilatation was defined as LV diastolic volume/BSA (Body surface area) of $> 100\text{mL/m}^2$ in men and $> 80\text{mL/m}^2$ in women, and LV systolic volume/BSA of $> 45\text{ mL/m}^2$ in men and $> 40\text{mL/m}^2$ in women) [7].

- For LA size, volume is calculated using modified biplane method (Severe LA dilatation was defined as LA volume/BSA $> 48\text{ mL/m}^2$) [7].

- For RV size, multiple acoustic windows for chamber quantification were used with inner-edge to inner-edge measurements (RV dilation was defined as $> 41, 35, 83, 30, 35$ and 27 at RV basal, mid, longitudinal dimensions, RVOT PLAX (RV outflow tract at parasternal long-axis view), RVOT proximal and distal diameters, respectively) [7]. Severe RV dilation was defined as RV/LV volume ratio ≥ 2.30 .

- For RV function, TAPSE (Tricuspid Annular Plane Systolic Excursion) and DTI-Derived Tricuspid Lateral Annular Systolic Velocity S' were used for assessment (RV dysfunction was defined as TAPSE $< 17\text{ mm}$ and/or Pulsed Doppler $S' < 9.5\text{ cm/sec}$) [7]. Moderate-severe RV dysfunction was defined as TAPSE $< 15\text{ mm}$.

- For Mitral Regurgitation (MR), significant MR was defined as grade III/IV (Effective Regurgitant Orifice Area (EROA) $> 0.30\text{ mm}^2$, Regurgitant Volume (RVol) $> 45\text{ mL}$ and Regurgitant Fraction (RF) $> 40\%$).

- A special zoom on the left ventricular (LV) apex was applied and harmonic imaging was used because the majority of thrombi were located at the apex

I- For DCM: Left ventricular ejection fraction (LVEF) <0.40 ($>2SD$) and/or fractional shortening <0.25 ($>2SD$), as well as a left ventricular end-diastolic diameter $>117\%$ of the estimated value corrected for age and body surface according to Henry equation: $(45-3(BSA)^{1/3} \cdot 0.03(\text{age})^{7 \cdot 2})$ which corresponds to 2 SD of the predicted normal limit $+5\%$ [8].

II- For ICM: Diagnostic criteria were similar to DCM in addition to coronary artery disease obstruction ($\geq 50\%$ narrowing of the diameter of the lumen of the left main coronary artery or $\geq 70\%$ narrowing of the diameter of the lumen of the left anterior descending coronary artery, left circumflex artery or right coronary artery).

III- for HCM: In the absence of secondary causes of hypertrophy (HTN, Aortic stenosis), it is diagnosed based on ≥ 15 mm wall thickness in one or more myocardial segments measured by echocardiography [9].

Exclusion criteria

All patients out of the scope of service and <18 years old were excluded.

All patients admitted before 2019 were excluded due to incomplete data.

All patients with other types of cardiomyopathy (restrictive, LV non-compaction, stress-induced cardiomyopathy, etc.) were excluded due to a very small number with incomplete data.

Patients with HCM were encountered in small numbers with different characteristics and were not addressed in the current study.

Clinical and hospital course data collected for all patients included the following

Demographic data: age, gender, body mass index (BMI), and status (residence/pilgrims).

Risk factors: diabetes mellitus (DM) [10], hypertension (HTN) [10], smoking, dyslipidemia (DLP) [10], presence of chronic kidney disease (CKD), old cerebrovascular accidents (CVA), and history of chronic obstructive pulmonary disease (COPD).

Clinical presentation and laboratory results: severe heart failure symptoms (New York Heart Association (NYHA) functional classification III/IV). Blood urea, serum creatinine, sodium, potassium, and brain natriuretic peptide (BNP) markers were all monitored.

Standard medications: beta-blockers (BB), spironolactone, angiotensin-converting enzymes inhibitors (ACEIs)/angiotensin-receptor blockers (ARBs), loop diuretics (Lasix), metolazone, digoxin.

Advanced treatment strategies including the use of advanced heart failure treatment and revascularization for ICM: advanced heart failure therapy was planned for selected patients who were fulfilled the following criteria-

Sacubitril/Valsartan (Entresto) for patients with NYHA Class II-IV and reduced ejection fraction without drug contraindications or limitations [5].

Device treatment using ICDs for primary or secondary prevention of sudden cardiac death and CRT-D for patients who remain in NYHA functional classes II and III despite optimal medical therapy with a wide QRS complex and reduced left ventricular ejection fraction (LVEF $\leq 30\%$ to 35%) [6].

Revascularization therapy for ICM patients includes percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG).

Hospital outcomes: in-hospital death, length of stay (LOS), left ventricular ejection fraction (LVEF) [7], pulmonary edema, cardiac arrest, cardiogenic shock, history of mechanical ventilation (MV), and history of left ventricular thrombus (LVT).

Statistical analysis

Statistical analysis was performed using the SPSS software package (SPSS Inc.; Chicago, IL) version 21.0. A descriptive statistical analysis was carried out by reporting the number and percentage for categorical variables and the mean and standard deviation for continuous variables. Demographic and clinical data, as well as close-ended questions, were summarized in frequency tables. In the comparison between DCM and ICM groups, a chi-squared test was used for categorical variables, while a t-test was used for continuous variables. For all analyses, a P-value of <0.05 was considered significant and a value of >0.05 was not

considered significant. For the multivariate analyses, we performed Poisson regression with an estimation of robust variances using stepwise methodology to calculate the incidence ratios and the 95% confidence intervals

Results

All patients underwent admission and investigation and were diagnosed with cardiomyopathy during their hospital stay in 2019 and 2020. They were divided into three groups: (1) dilated cardiomyopathy (DCM): 385 patients (36% of 1069); (2) ischemic cardiomyopathy (ICM): 663 patients (62% of 1069); and (3) hypertrophic cardiomyopathy (HOCM): 21 patients (2% of 1069), as shown in Figure 1.

FIGURE 1: Prevalence of different types of cardiomyopathy.

We compared patients with reduced left ventricular ejection fraction (LVEF <40%) with DCM versus ICM in terms of baseline clinical data, treatment, and in-hospital outcome measures.

Clinical data

As shown in Table 1, ICM patients were of an older age, showed higher a prevalence of both male gender and pilgrim status, and had more frequent cardiovascular risk factors when compared to DCM patients (P<0.001, 0.001, and 0.004 for DM, HTN, and CKD, respectively).

Variable	Dilated cardiomyopathy (DCM), N = 385 (36%)	Ischemic cardiomyopathy (ICM), N = 663 (62%)	P-value
Age (years)	50.39± 13.3	59.43± 11.6	<0.001
Male gender	265 (69%)	583 (88%)	<0.001
Pilgrims	4 (1%)	86 (13%)	<0.001
BMI (kg/m ²)	30.1±6.9	28.7±6.1	0.017
DM	181 (47%)	477 (72%)	<0.001
HTN	219 (57%)	471 (71%)	0.001
DLP	100 (26%)	179 (27%)	NS
Smoking	123(32%)	240 (36%)	NS
Family history of cardiomyopathy	21 (5.5%)	22 (3.3%)	NS
CKD	42 (11%)	141 (21%)	0.004
H/O CVA	54 (14%)	140 (21%)	NS
H/O COPD	23 (6%)	41 (6%)	NS
Serum urea (mg/dl)	55.32± 36.7	54.31± 34.8	NS
Serum creatinine (mg/dl)	1.1± 1.9	1.31± 1.5	0.04
Serum sodium (mg/dl)	137.35± 4.1	136.25± 3.2	<0.001
Serum potassium (mg/dl)	4.23± 0.4	4.23± 0.3	NS
BNP on admission (pg/ml)	1159.09± 2529.3	919.76± 1202.5	0.07

TABLE 1: Baseline demographic and clinical data of dilated and ischemic cardiomyopathy patients.

BMI: body mass index; BNP: brain natriuretic peptide; CKD: chronic kidney disease; COPD: chronic obstructive lung disease; CVA: cerebrovascular accidents; DLP: dyslipidemia; DM: diabetes mellitus; HTN: hypertension; NS: not significant.

No significant difference was found between the two groups regarding associated morbidities in the form of a history of CVA or COPD. ICM patients showed more hyponatremia ($P<0.001$) and higher serum creatinine ($P=0.04$) compared to DCM patients. Higher values of BNP were detected among DCM patients.

More than half of patients with DCM (431, 65%) presented with severe heart failure symptoms (NYHA class III/IV) and needed intensive anti-failure treatment; however, only a third (123, 32%) of ICM patients group had severe symptoms ($P<0.001$), as shown in Figure 2.

FIGURE 2: Severe heart failure symptom presentation in different types of cardiomyopathy.

DCM: dilated cardiomyopathy; ICM: ischemic cardiomyopathy; HF: heart failure.

The majority of ICM patients presented with chest pain and acute coronary syndrome (32% presented with ST-elevation myocardial infarction, 25% with non-ST-elevation myocardial infarction, and only 11% with unstable angina).

Table 2 shows that, when examined using echocardiography, patients with DCM had more deteriorated function (severe LA, LV, and RV dilatation [$P < 0.001$, < 0.001 , and 0.005 , respectively]), significant MR ($P = 0.02$), and lower LVEF ($P < 0.001$) compared to patients with ICM. No significant difference in RV systolic dysfunction nor left ventricular thrombus was noted between the two groups.

Variable	Dilated cardiomyopathy (DCM); N = 385 (36%)	Ischemic cardiomyopathy (ICM); N = 663 (62%)	P-value
Severe LV dilatation	135 (35%)	80 (12%)	< 0.001
Severe LA dilatation	89 (23%)	47 (7%)	< 0.001
Severe RV dilatation	27 (7%)	7 (1%)	0.005
Significant MR (III/IV)	150 (39%)	199 (30%)	0.02
LVEF%	25.8 $\pm$ 9.4	39.1 $\pm$ 9.1	< 0.001
Significant RV dysfunction	70 (18%)	93 (14%)	NS
LVT	35 (9%)	67 (10%)	NS

TABLE 2: Echocardiographic findings of dilated and ischemic cardiomyopathy patients.

LA: left atrium; LV: left ventricle; LVEF: left ventricular ejection fraction; LVT: left ventricular thrombus; MR: mitral regurgitation; RV: right ventricle; NS: not significant.

Management strategies

Aggressive diuretic treatment was used more often among DCM patients than ICM patients ($P = 0.001$ and < 0.001 for loop diuretics and spironolactone, respectively). Sacubitril/Valsartan was initiated and tolerated more frequently among DCM patients than ICM patients (177, 46% VS 145, 22%; $P < 0.001$). Moreover, in patients who were treated with Sacubitril/Valsartan, the dose could be titrated higher during the short-term follow-up period among DCM patients than among ICM patients (57% VS 29%; $P < 0.001$). Conversely,

ACEIs/ARBs were utilized more frequently among ICM patients than DCM patients (65% VS 45%; $P<0.001$). With regard to the prevention of sudden cardiac death and improving both quality of life as well as mortality, the utilization of device therapy (ICDs/CRTDs) was observed to be significantly higher among DCM patients than ICM patients (21% VS 11%; $P=0.001$), as shown in Table 3.

Variable	Dilated cardiomyopathy (DCM); N = 385 (36%)	Ischemic cardiomyopathy (ICM); N = 663 (62%)	P-value
Loop diuretics	323 (84%)	503 (76%)	0.001
Spironolactone	327 (85%)	424 (64%)	<0.001
Metolazone	23 (6%)	33 (5%)	NS
BB	355 (92%)	603 (91%)	NS
Digoxin	31 (8%)	13 (2%)	0.01
Sacubitril/Valsartan (Entresto)	177 (46%)	145 (22%)	<0.001
Titration of Entresto doses	219 (57%)	192 (29%)	<0.001
ACEi/ARBs	173 (45%)	431 (65%)	<0.001
Device therapy (ICD/CRTD)	81 (21%)	73 (11%)	0.001

TABLE 3: Anti-failure treatment for both dilated and ischemic cardiomyopathy patients.

ACEi: angiotensin-converting enzyme inhibitor; ARBs: angiotensin-receptor blockers; BB: beta-blockers; CRTD: cardiac resynchronization therapy device; ICD: implantable cardioverter-defibrillators; NS: not significant.

Moreover, in addition to standard treatment for ICM patients, revascularization strategies were utilized more frequently than conventional medical therapy (49% for PCI, 20% for CABG VS only 31% for medical treatment), as shown in Figure 3.

FIGURE 3: Treatment strategies selected for patients with ischemic cardiomyopathy.

CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention.

In-hospital outcome measures and mortality

ICM patients showed a higher prevalence of indication for mechanical ventilation during their hospital stay ($P=0.05$); however, DCM patients showed a higher rate of arrhythmias ($P=0.001$). The length of hospital stay did not differ between the two groups, nor did the prevalence of pulmonary edema, cardiogenic shock, or cardiac arrest in severe heart failure cases. The total in-hospital mortality was 16%, with a higher incidence among ICM patients than among DCM patients (19% VS 13%; $P = 0.001$), as shown in Table 4.

Variable	Dilated cardiomyopathy (DCM); N = 385(36%)	Ischemic cardiomyopathy (ICM); N = 663(62%)	P-value
Death	50 (13%)	126 (19%)	0.001
Mechanical ventilation	9 (2%)	53 (8%)	0.001
Arrhythmias	116 (30%)	113 (17%)	0.05
Pulmonary edema	23 (6%)	60 (9%)	NS
Cardiogenic shock	15 (4%)	40 (6%)	NS
Cardiac arrest	20 (5%)	47 (7%)	NS
Length of hospital stay (days)	11.16± 7.2	12. 15± 8.6	NS

TABLE 4: Hospital outcome measures for both dilated and ischemic cardiomyopathy patients.

NS: not significant.

According to the multivariate analysis, independent predictors of mortality among cardiomyopathy patients were age, renal impairment, and lower LVEF ($P= 0.04$, <0.001 , and 0.21 , respectively), as shown in Table 5.

Variable	RR (CI 95%)	P-value
Age	1.002 (1.000 – 1.004)	0.004
Male gender	1.074 (0.97 – 1.18)	0.14
Pilgrims	1.051 (0.96 – 1.15)	0.29
DM	0.999 (0.99 – 1.003)	0.82
HTN	1.022 (0.95 – 1.10)	0.55
CKD	1.22 (1.12 – 1.33)	<0.001
Serum sodium	0.996 (0.990 – 1.002)	0.23
LVEF%	1.081 (1.01 – 1.16)	0.02

TABLE 5: Multivariate analysis of the predictors of mortality.

CI: 95% confidence interval; CKD: chronic kidney disease; DM: diabetes mellitus; HTN: hypertension; LVEF: left ventricular ejection fraction; RR: relative risk.

Discussion

What is already known about this subject, and what does this study add?

Our center is the only cardiac center in the Mecca region providing tertiary care facilities including revascularization and advanced heart failure treatment. Because of this, it receives most of the cardiomyopathy patients deemed suitable for invasive assessment and advanced management. This led to a unique comparison between DCM and ICM patients regarding the severity, management, and outcome data.

The results of our study have shown that ICM patients were older than patients with DCM which can be explained by coronary artery disease mainly affecting a more elderly age group [11]. Atherosclerosis-inducing coronary artery disease (CAD) is the most common cause of ischemic cardiomyopathy in old age and is characterized by a decreased blood supply that carries oxygen and essential nutrients to cardiac muscles; this leads to deterioration of the cardiac muscle function and chamber remodeling or dilation, which eventually lead to congestive heart failure (CHF) [11,12]. Moreover, ICM is determined by several risk factors that include diabetes mellitus, hypertension, and renal impairment, as statistically proven in our study.

Interestingly, we found that DCM patients showed a more severe presentation and had a higher prevalence of arrhythmias, making them more frequent candidates for device therapy than ICM patients. This might be explained by the fact that the DCM phenotype is mainly characterized by left ventricular dilatation and contractile dysfunction in the absence of hypertensive, valvular, congenital heart disease, or significant CAD [13]; however, the progressive dilatation can lead to weakness in the heart muscle, which further lowers the ejection fraction and increases the stress on the ventricular wall. Once symptoms develop, DCM usually leads to decompensated heart failure, and it represents one of the most common causes of heart transplantation in the Western world. Often life-threatening arrhythmias and sudden cardiac death (SCD) can characterize the course of DCM or represent the abrupt onset of the disease [14].

Proper diagnosis and further workup of admitted cardiomyopathy patients are crucial for the management and implementation of advanced therapy. Concerning echocardiography, our study showed many disparities between ICM and DCM patients, such as LV dilatation and systolic dysfunction, which were found to be poorer among DCM patients than ICM patients; this was consistent with other studies [15]. Furthermore, in a study that aimed to differentiate between ischemic and non-ischemic cardiomyopathy patient markers, RV enlargement was one of the differential echocardiogram findings in non-ischemic dilated cardiomyopathy patients [16]. This was also similar to our findings.

The guideline-directed medical treatment recommended for all patients with decompensated heart failure includes diuretics, beta-blockers, renin-angiotensin system inhibitors (ACE inhibitor/ARB), and mineralocorticoid-receptor antagonists. Although Sacubitril/Valsartan is FDA approved for use in NYHA functional class II to IV patients with heart failure with reduced Ejection Fraction (HFrEF), data and guidance regarding its use are still limited [17]. Recently, a LIFE trial was designed to increase the amount of data regarding the safety and efficacy of Sacubitril/Valsartan in HFrEF patients. It also provided important information regarding its use in the management of patients with advanced HF [18]. This guided us in our study of the implementation of advanced therapy and its practical use among different heart failure patient populations. In our findings, DCM patients showed a higher need for advanced therapy, including Sacubitril/Valsartan. This is explained by the more severe symptoms that they presented with, and the lower recorded left ventricular ejection fractions noted in their echocardiograms compared to ischemic patients. Overall, the usage of higher doses of Sacubitril/Valsartan was the main goal in a tertiary care center follow-up of heart failure patients; this was limited by many factors such as side effects and noncompliance of the patients. The implementation of appropriate patient and clinician support pathways guides better uptake, dose-titration, and maintenance of evidence-based doses in clinical practice [19]. Our findings suggest that patients with DCM tolerate Sacubitril/Valsartan well, as evidenced by higher rates of dose titration compared to ICM patients. This can be explained by DCM patients being at a younger age with less associated morbidities, whereas ICM patients were elderly with multiple morbidities and had a higher prevalence of renal impairment, which limited drug use and dose titration among them. The long-term benefits of Sacubitril/Valsartan in the improvement of left ventricular ejection fraction among different types of cardiomyopathy patients have been explored in some recent trials and studies [20,21]. The long-term efficacy and safety of Sacubitril/Valsartan are not covered in the current study and will be a future topic of investigation.

In terms of device therapy, a retrospective cohort study that included 153 consecutive patients (48 non-ischemic cardiomyopathy, 105 ischemic cardiomyopathy) reported that non-ischemic patients received more device therapy than ischemic patients [22]. This finding agrees with ours, which suggested that device implantation is used more frequently among DCM patients than ICM patients. This again might be explained by the fact that severe heart failure presentation, lower recorded LVEF, and life-threatening arrhythmias were all reported mainly among DCM patients [14].

Patients with ischemic cardiomyopathy may benefit from revascularization. There was a 7% absolute reduction in overall mortality over a 10-year time between patients who had CABG versus standard medical treatment [23]. Another meta-analysis of 21 studies comparing medical therapy using PCI and CABG in patients with heart failure revealed the paucity of revascularization therapy in ischemic cardiomyopathy with a significant reduction in mortality, and this is independent of viability testing [24]. We believe that the rate of revascularization therapy in our current study among ICM patients was appropriate and followed the standard strategies. These findings highlight the importance of the appropriate utilization of tertiary services in qualified cardiac centers and adherence to treatment guidelines.

Overall, the prognosis of patients with cardiomyopathy depends on their disease state and chronicity. In ICM patients, a major component in the determination of their prognosis is myocardial viability and the use

of revascularization therapy [11]. In DCM scenarios, most patients eventually end up with chronic heart failure and become candidates for advanced therapy [25]. In a recent study [26], the ICM group showed higher mortality rates and were more likely to have in-hospital complications compared to the DCM group, which is consistent with our findings. This might be explained by ICM patients being more elderly, having multiple morbidities, and presenting fewer candidates for advanced heart failure therapy. However, DCM patients were younger, presenting more candidates for the advanced treatment and might have potential reversibility of their disease. In-hospital mortality was independently predicted by age, renal impairment, and lower LVEF, which is consistent with other studies in the literature [27-29]. This also highlights that although we had patients with different characteristics, we found that most of the predictors of in-hospital mortality in our sample were very similar to those previously published in other studies.

The results of our study should help to give the cardiovascular research community a deeper view of the prevalence, clinical manifestations, and severity of each type of cardiomyopathy, as well as how new approaches are most effectively used and allocated to the candidate patients. Our research also highlights the importance of increased awareness, implementation, and appropriate utilization of the advanced heart failure management and revascularization strategies that are available in tertiary centers.

Limitations

The present study had some limitations. Firstly, the number of enrolled patients was related to the nature of single-center and limited selection period, in addition to the situation of the COVID-19 pandemic. Secondly, selection bias cannot be excluded. Thirdly, no long-term follow-up data was collected due to the nature of tertiary care centers; most patients completed their follow-up in their primary and secondary hospitals. Finally, the number of non-ICM patients was small.

Recommendations

Studies of larger numbers of patients and/or multicenter studies are needed to confirm the results of the present study.

Conclusions

There are discrepancies in the prevalence, demographics, clinical characteristics, and outcomes between dilated and ischemic cardiomyopathy patients. Although DCM patients were younger and had fewer cardiovascular risk factors, they presented with more severe symptoms and dysfunction, making them more likely candidates for advanced heart failure treatment, and they showed better outcomes reflected by a lower mortality rate. Increased age, presence of renal dysfunction, and lower LVEF were found as independent predictors of in-hospital mortality.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. King Abdulla Medical City in Holy capital, Institutional Review Board issued approval 20-660. Dear Dr. Sheeren, Cardiomyopathy Management in a Tertiary Care Center: Clinical Components and Venues of Care, KAMC, Makkah, Saudi Arabia. 2.0 DR. Sheeren Mohammed 20-660 NA This is to inform you that the above mentioned proposal has been the subject of exemption from review by KAMC IRB registered at the National BioMedical Ethics Committee, King Abdulaziz City for Science and Technology on 14-07-1433 (Registration no. H-02-K-001) and is following the GCP-ICH regulations (OHRP Registration no. IORG0007625). The decision of exemption from review was based on the following submitted documents: 1. The Initial documents submitted on 07-Jul-2020 : ☑ The protocol version 1.0 ☑ The Data collection form version 1.0 2. Amendment request for exemption submitted in 07-Sep-2021: ☑ IRB-002 FR2 Application for IRB Approval of CMP Research Amendment. (Dated 05-Sep-2021) ☑ IRB-002-FR5-V1 Progress Report for Retrospective Studies Form (Dated 05-Sep-2021) ☑ The protocol. (Version 2.0 Dated 06-Sep-2021) The opinion of the IRB is to approve this proposal with its current design: ☑ The study is approved for one year from the date of this letter. Extension can be requested one month before the expiry of the approval. ☑ To conduct research as per the approved documents. ☑ Amendments to the approved documents require IRB approval before implementation. ☑ End of study report is expected before expiration of approval. ☑ The study conduct may be subject to audits by KAMC Human Research Protection Program (HRPP). ☑ Research participant confidentiality should be protected at all times and may be subject to audits by KAMC HRPP. ☑ Document retention: all study documents should be kept by the principal investigator for a period of three years from General study completion. Approval conditions: If your study involves subject consent: Copy of all consents should be submitted to IRB ☑ If subject's clinical photo would be used for publication or presentation additional patient consent will be required and should be submitted to IRB before publication. N.B.: Please note that this letter gives you ethical clearance to perform your study according to the approved documents; you still need to obtain necessary administrative approval from the site/s where the study will be conducted. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from

any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Elliott P, Andersson B, Arbustini E, et al.: Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J*. 2008, 29:270-6. [10.1093/eurheartj/ehm342](https://doi.org/10.1093/eurheartj/ehm342)
2. Maron BJ, Towbin JA, Thiene G, et al.: Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. *Circulation*. 2006, 113:1807-16. [10.1161/CIRCULATIONAHA.106.174287](https://doi.org/10.1161/CIRCULATIONAHA.106.174287)
3. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE: Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. *Circulation*. 1995, 92:785-9. [10.1161/01.cir.92.4.785](https://doi.org/10.1161/01.cir.92.4.785)
4. Roberts WC: The coronary arteries and left ventricle in clinically isolated angina pectoris: a necropsy analysis. *Circulation*. 1976, 54:388-90. [10.1161/01.cir.54.3.388](https://doi.org/10.1161/01.cir.54.3.388)
5. Paolini C, Perrone C, Pellizzari CA, Randon ML, Bilato C: Management of a patient with heart failure by sacubitril/valsartan: improvement of functional capacity. *Curr Med Res Opin*. 2019, 35:7-8. [10.1080/03007995.2019.1576482](https://doi.org/10.1080/03007995.2019.1576482)
6. Barsheshet A, Goldenberg I, Moss AJ, et al.: Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. *Eur Heart J*. 2011, 32:1622-30. [10.1093/eurheartj/ehq407](https://doi.org/10.1093/eurheartj/ehq407)
7. Lang RM, Badano LP, Mor-Avi V, et al.: Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015, 28:1-39.e14. [10.1016/j.echo.2014.10.003](https://doi.org/10.1016/j.echo.2014.10.003)
8. Manolio TA, Baughman KL, Rodeheffer R, et al.: Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). *American Journal of Cardiology*. 1992, 69:1458-66. [10.1016/0002-9149\(92\)90901-a](https://doi.org/10.1016/0002-9149(92)90901-a)
9. Elliott PM, Anastakis A, Borger MA, et al.: 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J*. 2014, 35:2733-79. [10.1093/eurheartj/ehu284](https://doi.org/10.1093/eurheartj/ehu284)
10. Bays HE, Chapman RH, Grandy S: The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. *Int J Clin Pract*. 2007, 61:737-47. [10.1111/j.1742-1241.2007.01536.x](https://doi.org/10.1111/j.1742-1241.2007.01536.x)
11. Bhandari B, Rodriguez BS, Masood W: Ischemic Cardiomyopathy. StatPearls Publishing, Treasure Island, FL; 2020.
12. Fang CY, Chen HC, Chen YL, et al.: Comparison of ventricular tachyarrhythmia recurrence between ischemic cardiomyopathy and dilated cardiomyopathy: a retrospective study. *PeerJ*. 2018, 6:e5312. [10.7717/peerj.5312](https://doi.org/10.7717/peerj.5312)
13. Reichart D, Magnussen C, Zeller T, Blankenberg S: Dilated cardiomyopathy: from epidemiologic to genetic phenotypes: a translational review of current literature. *J Intern Med*. 2019, 286:362-72. [10.1111/joim.12944](https://doi.org/10.1111/joim.12944)
14. Merlo M, Cannatà A, Vitagliano A, Zambon E, Lardieri G, Sinagra G: Clinical management of dilated cardiomyopathy: current knowledge and future perspectives. *Expert Rev Cardiovasc Ther*. 2016, 14:137-40. [10.1586/14779072.2016.1125292](https://doi.org/10.1586/14779072.2016.1125292)
15. Zuo H, Zhang Y, Ma F, et al.: Myocardial deformation pattern differs between ischemic and non-ischemic dilated cardiomyopathy: the diagnostic value of longitudinal strains. *Ultrasound Med Biol*. 2020, 46:233-43. [10.1016/j.ultrasmedbio.2019.10.006](https://doi.org/10.1016/j.ultrasmedbio.2019.10.006)
16. Katikireddy CK, Acharya T: Myocardial segmental thickness variability on echocardiography is a highly sensitive and specific marker to distinguish ischemic and non-ischemic dilated cardiomyopathy in new onset heart failure. *Int J Cardiovasc Imaging*. 2019, 35:791-8. [10.1007/s10554-018-01515-3](https://doi.org/10.1007/s10554-018-01515-3)
17. Yancy CW, Jessup M, Bozkurt B, et al.: 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Am Coll Cardiol*. 2017, 70:776-803. [10.1016/j.jacc.2017.04.025](https://doi.org/10.1016/j.jacc.2017.04.025)
18. Mann DL, Greene SJ, Givertz MM, et al.: Sacubitril/Valsartan in advanced heart failure with reduced ejection fraction: rationale/design of the LIFE trial. *JACC Heart Fail*. 2020, 8:789-99. [10.1016/j.jchf.2020.05.005](https://doi.org/10.1016/j.jchf.2020.05.005)
19. Du AX, Westerhout CM, McAlister FA, et al.: Titration and tolerability of Sacubitril/Valsartan for patients with heart failure in clinical practice. *J Cardiovasc Pharmacol*. 2019, 73:149-54. [10.1097/FJC.0000000000000643](https://doi.org/10.1097/FJC.0000000000000643)
20. Ioannou A, Metaxa S, Simon S, Mandal AK, Missouris CG: Comparison of the effect of Sacubitril/Valsartan on left ventricular systolic function in patients with non-ischaemic and ischaemic cardiomyopathy. *Cardiovasc Drugs Ther*. 2020, 34:755-62. [10.1007/s10557-020-07036-3](https://doi.org/10.1007/s10557-020-07036-3)
21. Rao VU, Dobariya V, Patel K, et al.: Predictors of left ventricular function improvement in patients prescribed Sacubitril/Valsartan in a tertiary-care community-based heart failure cohort. *J Cardiac Fail*. 2019, 25:150-10. [10.1016/j.cardfail.2019.07.433](https://doi.org/10.1016/j.cardfail.2019.07.433)
22. Evonich RF, Maheshwari A, Gardiner JC, et al.: Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia. *J Intervent Cardiac Electrophysiol*. 2004, 11:59-65. [10.1023/B:JICE.0000035931.10063.50](https://doi.org/10.1023/B:JICE.0000035931.10063.50)

23. Velazquez EJ, Lee KL, Deja MA, et al.: Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med*. 2011, 364:1607-16. [10.1056/NEJMoa1100356](#)
24. Wolff G, Dimitroulis D, Andreotti F, et al.: Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis. *Circ Heart Fail*. 2017, 10:e003255. [10.1161/CIRCHEARTFAILURE.116.003255](#)
25. Mahmaljy H, Yelamanchili VS, Singhal M: Dilated cardiomyopathy. StatPearls Publishing, Treasure Island, FL; 2020.
26. Wu F, Li P: Patient characteristics and in-hospital outcomes of heart failure with ischemic versus non-ischemic cardiomyopathy. *J Cardiac Fail*. 2019, 25:S70. [10.1016/j.cardfail.2019.07.200](#)
27. Alem MM: Predictors of mortality in patients with chronic heart failure: Is hyponatremia a useful clinical biomarker?. *Int J Gen Med*. 2020, 13:407-17. [10.2147/IJGM.S260256](#)
28. Wajner A, Zuchinali P, Olsen V, Polanczyk CA, Rohde LE: Causes and predictors of in-hospital mortality in patients admitted with or for heart failure at a tertiary hospital in Brazil. *Arq Bras Cardiol*. 2017, 109:321-30. [10.5935/abc.20170136](#)
29. Breathett K, Allen LA, Udelson J, Davis G, Bristow M: Changes in left ventricular ejection fraction predict survival and hospitalization in heart failure with reduced ejection fraction. *Circ Heart Fail*. 2016, 9:e002962. [10.1161/CIRCHEARTFAILURE.115.002962](#)